Unicycive Therapeutics (UNCY) Cash & Equivalents (2021 - 2026)

Unicycive Therapeutics has reported Cash & Equivalents for 6 years, with the latest figure at $37.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 89.04% year-over-year to $37.4 million; the trailing twelve-month figure through Mar 2026 stood at $37.4 million (up 89.04% YoY), and the FY2025 full-year result was $29.2 million, up 11.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $37.4 million, up from $29.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $48.9 million in Q1 2024, with the low at $455000.0 in Q4 2022.
• Historically, Cash & Equivalents has averaged $23.5 million across 5 years, with a median of $22.3 million in 2025.
• The largest YoY upside for Cash & Equivalents was 1057200.0% in 2022 against a maximum downside of 97.26% in 2022.
• Unicycive Therapeutics' Cash & Equivalents stood at $455000.0 in 2022, then surged by 2032.09% to $9.7 million in 2023, then jumped by 169.48% to $26.1 million in 2024, then rose by 11.69% to $29.2 million in 2025, then advanced by 27.99% to $37.4 million in 2026.
• The last three Cash & Equivalents figures came in at $37.4 million (Q1 2026), $29.2 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.